SCHEMBL3017698

SCHEMBL3017698

Cc1cccc(C)c1-c1csc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.56
ALDH1A1 P00352 5/20 0.56
MAPT P10636 5/20 0.56
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
L3MBTL1 Q9Y468 1/20 0.53
USP2 O75604 2/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAPK1 P28482 4/20 0.51
GBA1 P04062 1/20 0.47
RAB9A P51151 1/20 0.44
PKM P14618 2/20 0.43
TSHR P16473 3/20 0.42
HTT P42858 3/20 0.42
AR P10275 1/20 0.42
FAAH O00519 1/20 0.41
POLB P06746 3/20 0.41
PKLR P30613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010515 0.92 SMN1; SMN2 (0.53) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3015046 0.91 SMN1; SMN2 (0.55) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3014560 0.91 ALDH1A1 (0.56) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3019779 0.89 MAPT (0.53) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3010835 0.89 ALDH1A1 (0.55) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3019417 0.86 MAPT (0.60) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3015535 0.86 ALDH1A1 (0.57) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3006504 0.85 ALDH1A1 (0.72) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3012636 0.85 SMN1; SMN2 (0.60) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3012992 0.85 ALDH1A1 (0.59) LMNAALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885ALDH1A1 3510/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.